Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedMay 30, 2026
DataAggregated Company Financials
Companies17
  • 7D-1.1%
  • 3M-12.4%
  • 1Y20.1%
  • YTD0.6%

Over the last 7 days, the Pharma industry has dropped 1.1%, driven by a pullback from AstraZeneca of 0.8%. In the past year, the industry has gained 20%. As for the next few years, earnings are expected to grow by 11% per annum.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 30 May 2026UK£324.7bUK£91.8bUK£15.8b17.9x20.6x3.5x
Mon, 27 Apr 2026UK£334.5bUK£90.2bUK£15.5b19x21.6x3.7x
Wed, 25 Mar 2026UK£330.1bUK£90.7bUK£15.6b20.9x21.1x3.6x
Fri, 20 Feb 2026UK£368.6bUK£90.4bUK£15.4b23.8x23.9x4.1x
Sun, 18 Jan 2026UK£329.1bUK£89.7bUK£14.6b21.3x22.5x3.7x
Tue, 16 Dec 2025UK£323.0bUK£89.7bUK£14.6b21.6x22.1x3.6x
Thu, 13 Nov 2025UK£322.5bUK£90.5bUK£14.8b22.1x21.8x3.6x
Sat, 11 Oct 2025UK£300.1bUK£88.0bUK£11.8b19.8x25.5x3.4x
Mon, 08 Sep 2025UK£285.8bUK£87.5bUK£11.7b22x24.4x3.3x
Wed, 06 Aug 2025UK£268.5bUK£88.1bUK£11.5b28.1x23.4x3x
Fri, 04 Jul 2025UK£254.8bUK£86.0bUK£10.6b25.5x24.1x3x
Sun, 01 Jun 2025UK£271.4bUK£86.5bUK£10.6b27.3x25.5x3.1x
Tue, 29 Apr 2025UK£261.1bUK£86.0bUK£9.5b27.4x27.4x3x
Thu, 27 Mar 2025UK£276.1bUK£87.9bUK£9.7b31.9x28.5x3.1x
Sat, 22 Feb 2025UK£283.5bUK£88.7bUK£9.4b30.9x30x3.2x
Mon, 20 Jan 2025UK£232.8bUK£76.8bUK£8.0b31.8x29.3x3x
Wed, 18 Dec 2024UK£224.6bUK£74.8bUK£7.7b31.6x29.1x3x
Fri, 15 Nov 2024UK£222.0bUK£75.0bUK£7.7b30.9x28.7x3x
Sun, 13 Oct 2024UK£250.3bUK£72.2bUK£9.0b31.1x27.7x3.5x
Tue, 10 Sep 2024UK£272.4bUK£72.2bUK£9.0b40x30.2x3.8x
Thu, 08 Aug 2024UK£267.0bUK£73.3bUK£9.1b38.8x29.4x3.6x
Sat, 06 Jul 2024UK£256.0bUK£71.2bUK£9.5b31.6x26.9x3.6x
Mon, 03 Jun 2024UK£268.8bUK£71.4bUK£9.6b31.8x28.1x3.8x
Wed, 01 May 2024UK£263.1bUK£71.8bUK£10.1b31.5x26.2x3.7x
Fri, 29 Mar 2024UK£245.1bUK£70.8bUK£9.7b31.8x25.2x3.5x
Sun, 25 Feb 2024UK£236.1bUK£70.6bUK£9.6b33.7x24.5x3.3x
Tue, 23 Jan 2024UK£238.9bUK£68.9bUK£10.7b36.6x22.4x3.5x
Thu, 21 Dec 2023UK£232.9bUK£69.1bUK£10.7b34.9x21.8x3.4x
Sat, 18 Nov 2023UK£227.8bUK£69.8bUK£10.8b53.7x21.1x3.3x
Mon, 16 Oct 2023UK£245.7bUK£70.8bUK£10.4b56.6x23.7x3.5x
Wed, 13 Sep 2023UK£239.5bUK£69.7bUK£10.3b53.5x23.4x3.4x
Fri, 11 Aug 2023UK£244.0bUK£69.0bUK£10.2b52.8x24x3.5x
Sun, 09 Jul 2023UK£223.4bUK£67.4bUK£7.8b52.7x28.5x3.3x
Tue, 06 Jun 2023UK£252.0bUK£68.6bUK£8.0b55.5x31.6x3.7x
Price to Earnings Ratio

31.6x


Total Market Cap: UK£252.0bTotal Earnings: UK£8.0bTotal Revenue: UK£68.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 25.4x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 20.6x which is lower than its 3-year average PE of 25.4x.
  • The industry is trading close to its 3-year average PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 10% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market-0.27%
Healthcare-1.07%
Pharma-1.13%
Pharma-1.13%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
HIK Hikma PharmaceuticalsUK£14.761.2%
+UK£16.6m		-31.0%PE10.5x
SAR Sareum HoldingsUK£0.2522.0%
+UK£6.2m		75.4%PB29x
POLB Poolbeg PharmaUK£0.05916.1%
+UK£5.7m		82.8%PB4.8x
ANCR Animalcare GroupUK£3.330.5%
+UK£1.0m		18.9%PE45.3x
NFX NuformixUK£0.002120.6%
+UK£913.4k		86.4%PB3.3x

Latest News

GSK
UK£18.82
GSK
7D
-1.7%
1Y
24.9%
AZN
UK£138.02
AstraZeneca
7D
-0.8%
1Y
28.7%
HCM
UK£1.75
HUTCHMED (China)
7D
-1.5%
1Y
-15.5%
Narrative Update • May 28

HCM: Late-Stage Hematology And Oncology Pipeline Will Drive Future Re-Rating Potential

Analysts have kept their fair value estimate for HUTCHMED (China) steady at £3.46 per share, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. Together, these factors support an unchanged price target narrative.
STX
UK£0.059
Shield Therapeutics
7D
-6.3%
1Y
147.9%
Narrative Update • May 21

STX: Pediatric And Asia Regulatory Milestones Will Drive Future Earnings Upside

Shield Therapeutics’ latest analyst price target has been set at £0.14, with analysts attributing this unchanged fair value to a slightly adjusted discount rate, modestly revised revenue growth and profit margin assumptions, and a recalibrated future P/E multiple. What's in the News MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc., enrolled the first patient in a Phase II exploratory clinical trial in Japan evaluating ACCRUFeR (ferric maltol) for Pulmonary Arterial Hypertension.
ANCR
UK£3.33
Animalcare Group
7D
0.5%
1Y
18.9%
HIK
UK£14.76
Hikma Pharmaceuticals
7D
1.2%
1Y
-31.0%
Narrative Update • May 18

HIK: Buyback And Index Move Will Support Future Re Rating

Narrative update Hikma Pharmaceuticals' analyst price targets have been reset lower, with updates such as the move from £23.00 to £18.00 and from £24.00 to £20.00, as analysts factor in a slightly higher discount rate and modestly adjusted long term valuation assumptions while maintaining broadly constructive views on the stock. Analyst Commentary Recent Street research on Hikma Pharmaceuticals points to a recalibration of valuation, with price targets reduced but positive ratings maintained, including an Overweight rating from JPMorgan.
POLB
UK£0.059
Poolbeg Pharma
7D
16.1%
1Y
82.8%
HLN
UK£3.37
Haleon
7D
-2.1%
1Y
-18.7%
Narrative Update • May 10

HLN: Cash Returns And China Expansion Will Support Future Premium Re Rating

Haleon's updated analyst price target of £5.12, which compares with prior targets in the £4.40 to £5.17 range, reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E as analysts reassess the stock following recent mixed target changes across the Street. Analyst Commentary Recent Street research on Haleon presents a mixed picture, but there are clear pockets of optimism as some bullish analysts fine tune their targets around current valuation frameworks.
FUM
UK£0.0065
Futura Medical
7D
-3.0%
1Y
-92.9%
EAH
UK£0.95
ECO Animal Health Group
7D
-1.5%
1Y
56.6%
NFX
UK£0.0021
Nuformix
7D
20.6%
1Y
86.4%
SAR
UK£0.25
Sareum Holdings
7D
22.0%
1Y
75.4%
INC
UK£0.013
Incanthera
7D
6.3%
1Y
-74.5%